Efficacy and Safety of Poly-L-lactic Acid for Midface Rejuvenation: A 12-Month Split-face Controlled Evaluation With 3D Imaging and Patient-reported Outcomes
Aesthetic Surgery Journal · 2026
DOI: 10.1093/asj/sjag039 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Aesthetic Surgery Journal, 2026. Verfasst von Martina Ponzo und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Polyesters, Rejuvenation, Skin Aging, Cosmetic Techniques. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Poly-L-lactic acid (PLLA) is a biostimulatory injectable that restores midfacial volume through collagen neogenesis rather than gel-based filling. Controlled clinical evidence directly quantifying PLLA's volumetric efficacy remains limited.
Objectives
To evaluate the efficacy, safety, and patient-reported outcomes of a Norberg Medical PLLA formulation for midface rejuvenation in a prospective, evaluator-blinded, split-face controlled study. Participants were enrolled between July 2024 and September 2024, with follow-up completed in September 2025.
Methods
Ninety-five patients underwent three standardized PLLA sessions on one hemiface and saline placebo on the contralateral side. Each vial contained 150 mg PLLA in spherical microparticles, reconstituted with 5 mL sterile water without lidocaine. Assessments included Wrinkle Severity Rating Scale (WSRS), Vectra H1 3D volumetry (malar, zygomatic, mandibular), FACE-Q, and Global Aesthetic Improvement Scale (GAIS). Two blinded evaluators rated WSRS. Statistical analysis included paired testing, responder rates (≥1-grade WSRS improvement), and inter-rater reliability (ICC).
Results
At 12 months, PLLA-treated sides showed significant WSRS reduction vs baseline and saline control (Δ = −0.68, P < .001). 3D analysis confirmed sustained volumetric enhancement across all midface subunits. Inter-rater reliability was excellent (ICC = 0.91), and 82.1% achieved ≥1-grade WSRS improvement. Patient satisfaction remained high, mirroring objective findings. Adverse events were mild and transient, with no granulomas, nodules, or vascular events recorded.
Conclusions
Controlled split-face evaluation demonstrated that standardized PLLA treatment yields measurable, long-lasting midfacial volume restoration with excellent safety and high patient satisfaction. No granulomas or delayed-onset nodules were observed in this 12-month, 95-patient cohort, supporting a favorable safety profile for this PLLA formulation under these study conditions. Level of Evidence: 2 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Martina Ponzo, Adriano Santorelli
Zitieren
APA
Ponzo, M., Lombardi, M., Avvedimento, S., D'Alessio, F. M., Cavallini, M., & Santorelli, A. (2026). Efficacy and Safety of Poly-L-lactic Acid for Midface Rejuvenation: A 12-Month Split-face Controlled Evaluation With 3D Imaging and Patient-reported Outcomes. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjag039
Vancouver
Ponzo M, Lombardi M, Avvedimento S, D'Alessio FM, Cavallini M, Santorelli A. Efficacy and Safety of Poly-L-lactic Acid for Midface Rejuvenation: A 12-Month Split-face Controlled Evaluation With 3D Imaging and Patient-reported Outcomes. Aesthetic Surgery Journal. 2026. doi:10.1093/asj/sjag039
BibTeX
@article{Ponzo2026,
author = {Ponzo, Martina and Lombardi, Mariagiovanna and Avvedimento, Stefano and D'Alessio, Federico M and Cavallini, Maurizio and Santorelli, Adriano},
title = {Efficacy and Safety of Poly-L-lactic Acid for Midface Rejuvenation: A 12-Month Split-face Controlled Evaluation With 3D Imaging and Patient-reported Outcomes},
journal = {Aesthetic Surgery Journal},
year = {2026},
doi = {10.1093/asj/sjag039}
}
EUVIMED